Cardiff Oncology (CRDF) Stock Price, News & Analysis

Company Overview

Cardiff Oncology, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development. These candidates target pathways implicated in tumor immune evasion, with the goal of inducing immunogenic cell death and improving response rates. The company’s strategic approach emphasizes combination regimens, pairing its agents with established immunotherapies to potentially increase efficacy in solid tumors.

Since its founding in 2015, Cardiff Oncology has pursued strategic collaborations to accelerate its programs, notably entering a research agreement with Merck & Co. to explore combination studies with pembrolizumab. The company conducts its clinical trials across multiple sites in the United States and internationally, serving a global oncology community committed to developing new therapeutic options for patients with cancer.

Key Stats

• Today's Range: $2.00 to $2.10
• 50-Day Range: $1.95 to $4.45
• 52-Week Range: $1.90 to $5.64
• Volume: 501,249 shs
• Average Volume: 1.00 million shs
• Market Capitalization: $133.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.63
• Consensus Rating: Moderate Buy

Cardiff Oncology Stock Analysis - MarketRank™

Cardiff Oncology scored higher than 54% of companies evaluated by MarketBeat, and ranked 535th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cardiff Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Cardiff Oncology has a consensus price target of $10.63, representing about 428.6% upside from its current price of $2.01.

Amount of Analyst Coverage

Cardiff Oncology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cardiff Oncology are expected to grow in the coming year, from ($0.99) to ($0.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cardiff Oncology is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cardiff Oncology is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cardiff Oncology has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.91% of the float of Cardiff Oncology has been sold short.

Short Interest Ratio / Days to Cover

Cardiff Oncology has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Cardiff Oncology has recently increased by 1.34%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiff Oncology does not currently pay a dividend.

Dividend Growth

Cardiff Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

25.91% of the float of Cardiff Oncology has been sold short.

Short Interest Ratio / Days to Cover

Cardiff Oncology has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Cardiff Oncology has recently increased by 1.34%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Cardiff Oncology has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cardiff Oncology this week, compared to 2 articles on an average week.

Search Interest

17 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 113% compared to the previous 30 days.

MarketBeat Follows

2 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Cardiff Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $710,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 7.70% of the stock of Cardiff Oncology is held by insiders.

Percentage Held by Institutions

Only 16.29% of the stock of Cardiff Oncology is held by institutions.

CRDF Stock Analysis - Frequently Asked Questions

How have CRDF shares performed this year?

Cardiff Oncology's stock was trading at $4.34 at the beginning of the year. Since then, CRDF shares have decreased by 53.7% and is now trading at $2.01.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) released its quarterly earnings data on Tuesday, July, 29th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. The company earned $0.12 million during the quarter, compared to analysts' expectations of $0.11 million. Cardiff Oncology had a negative net margin of 9,344.14% and a negative trailing twelve-month return on equity of 77.94%.

Who are Cardiff Oncology's major shareholders?

Cardiff Oncology's top institutional shareholders include Blair William & Co. IL (3.79%), Geode Capital Management LLC (2.25%), Adage Capital Partners GP L.L.C. (2.14%) and Acorn Capital Advisors LLC (2.12%). Insiders that own company stock include Gary W Pace, Lale White and Mark Erlander.
View institutional ownership trends.

How do I buy shares of Cardiff Oncology?

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRDF
• CIK: 1213037
• Web: cardiffoncology.com
• Phone: (858) 952-7570
• Fax: N/A
• Employees: 20
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cardiff Oncology: $10.63
• High Price Target: $19.00
• Low Price Target: $3.50
• Potential Upside/Downside: +428.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.43 million
• Net Margins: -9,344.14%
• Pretax Margin: -9,344.14%
• Return on Equity: -77.94%
• Return on Assets: -63.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.42
• Quick Ratio: 4.42

Sales & Book Value

• Annual Sales: $680 thousand
• Price / Sales: 196.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.86 per share
• Price / Book: 1.08

Miscellaneous

• Outstanding Shares: 66,530,000
• Free Float: 61,403,000
• Market Cap: $133.73 million
• Optionable: Optionable
• Beta: 1.28